title: Building a personalized medicine infrastructure at a major cancer center.
abstract: Our understanding of cancer biology is rapidly increasing, as is the availability and affordability of high throughput technologies for comprehensive molecular characterization of tumors and the individual's own genetic makeup. Thus, the time is right to implement personalized molecular medicine for all patients with cancer. Personalized approaches span the full cancer care spectrum from risk stratification to prevention, screening, therapy, and survivorship programs. Several molecular therapeutics have entered clinical trials creating a huge opportunity to couple genomic markers with this emerging drug tool kit. The number of patients managed in major cancer centers creates a challenge to the implementation of genomic technologies required to successfully deliver on the promise of personalized cancer care. This requires a major investment in infrastructure to facilitate rapid deployment of multiplex, cost-effective, and tissue-sparing assays relevant across multiple tumor lineages in the Clinical Laboratory Improvement Amendments (CLIA) environment. Efforts must be made to ensure that assays are accessible to patients most likely to be enrolled onto molecular-marker-driven trials and that the tests are billable and payable, which will make them accessible to a wide range of patients. As the number of patients and aberrations increase, it will become critical to provide decision support for genomic medicine. Institutional commitment is needed to optimize accessibility and quality of research biopsies and to facilitate novel personalized cancer therapy trials. This article will focus on the challenges and opportunities that accompany the building of infrastructure for personalized cancer therapy.
authors.affiliation: University of Texas MD Anderson Cancer Center, 1400 Pressler St, FCT17.5030, Houston, TX 77030, USA. Fmeric@mdanderson.org
authors.forename: Funda
authors.initials: F
authors.lastname: Meric-Bernstam
authors.forename: Carol
authors.initials: C
authors.lastname: Farhangfar
authors.forename: John
authors.initials: J
authors.lastname: Mendelsohn
authors.forename: Gordon B
authors.initials: GB
authors.lastname: Mills
mesh_terms: D002984:Clinical Laboratory Information Systems / Q000592:standards; D019411:Clinical Laboratory Techniques / Q000592:standards; D023281:Genomics / Q000379:methods*; D006801:Humans; D008495:Medical Oncology / Q000379:methods*; D062346:Molecular Medicine / Q000379:methods*; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D057285:Precision Medicine / Q000379:methods*; D057170:Translational Research, Biomedical / Q000379:methods / Q000592:standards